Saturday 17 October 2026
Export VRXA’s income statement to Excel — free account
Veraxa Biotech AG
VRXA Healthcare Biotechnology
Insiders bought in the last twelve months.
1.11
0.01
+0.91%
Follow VRXA
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | 9.95 | 10.03 | 1.04 |
Analyst estimates 2027–2029 Powerpack |
|||
| High | — | — | — | — | — | — | — | 11.20 | 10.99 | 27.36 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | — | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | — | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | — | — | — | — | — | — | |||||
| EBT margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| Net income | — | — | — | — | — | — | — | — | — | — | |||||
| Depreciation | — | — | — | — | — | — | — | — | — | — | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Earnings | — | — | — | — | — | — | — | — | — | — | |||||
| Cash flow | — | — | — | — | — | — | — | — | — | — | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | — | — | — | — | — | — | — | — | — | — | |||||
| Book value | — | — | — | — | — | — | — | — | — | — | |||||
| Shares, m | — | — | — | — | — | — | — | — | — | — | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | — | — | ||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | — | — | — | — | — | — | — | — | — | — | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | — | — | ||||
| Total debt | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | — | — | — | — | — | — | — | — | — | — | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | — | — | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | — | — | ||||
| ROIC | — | — | — | — | — | — | — | — | — | — | |||||
| ROE | — | — | — | — | — | — | — | — | — | — | |||||
Negative figures in brackets.
Charts ten years each
Veraxa Biotech AG vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ORMP Oramed Pharmaceuticals Inc. | $173.9M | 1.0× | — (loss-making) | +193.26% (above 0%: growing) | +493.75% (above 0%: growing) | +94.29% (above 0%: growing) | 0.65% | 0.00% | Compare |
| WHWK Whitehawk Therapeutics, Inc. | $173.3M | — (loss-making) | — (loss-making) | +33.48% (above 0%: growing) | n/m | +72.57% (above 0%: growing) | 89.36% | 0.00% | Compare |
| DTIL Precision BioSciences, Inc. | $170.3M | — (loss-making) | — (loss-making) | +37,272.41% (above 0%: growing) | n/m | +33.73% (above 0%: growing) | 100.00% | 0.00% | Compare |
| CHRS Coherus Oncology, Inc. | $165.3M | — (loss-making) | — (loss-making) | +39.53% (above 0%: growing) | n/m | −33.15% (below 0%: shrinking) | 70.35% | (225.98%) | Compare |
| IPHA Innate Pharma S.A. Sponsored ADR | $165.3M | — (loss-making) | — | +246.29% (above 0%: growing) | +106.08% (above 0%: growing) | −929.03% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| VRXA Veraxa Biotech AG | $162.5M | — | — | — | — | — | — | — | |
| CMPX Compass Therapeutics, Inc. | $161.5M | — (loss-making) | — (loss-making) | — | n/m | −26.05% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| ADAG Adagene Inc. Sponsored ADR | $161.1M | — (loss-making) | — (loss-making) | — | — | −11.08% (below 0%: shrinking) | — | — | Compare |
| MDWD MediWound Ltd. | $157.6M | — (loss-making) | — (loss-making) | −45.83% (below 0%: shrinking) | n/m | −49.90% (below 0%: shrinking) | 10.90% | (305.89%) | Compare |
| Median of peers | $165.3M | — | — | +116.40% | — | −18.56% | 70.35% | 0.00% |